"Oxidopamine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A neurotransmitter analogue that depletes noradrenergic stores in nerve endings and induces a reduction of dopamine levels in the brain. Its mechanism of action is related to the production of cytolytic free-radicals.
| Descriptor ID |
D016627
|
| MeSH Number(s) |
D02.092.311.342.478.650
|
| Concept/Terms |
Oxidopamine- Oxidopamine
- 6-Hydroxydopamine
- 6 Hydroxydopamine
- 6-OHDA
|
Below are MeSH descriptors whose meaning is more general than "Oxidopamine".
Below are MeSH descriptors whose meaning is more specific than "Oxidopamine".
This graph shows the total number of publications written about "Oxidopamine" by people in this website by year, and whether "Oxidopamine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 1 | 0 | 1 |
| 2000 | 0 | 1 | 1 |
| 2004 | 1 | 0 | 1 |
| 2005 | 0 | 2 | 2 |
| 2006 | 2 | 0 | 2 |
| 2007 | 0 | 1 | 1 |
| 2020 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Oxidopamine" by people in Profiles.
-
Castello J, Cort?s M, Malave L, Kottmann A, Sibley DR, Friedman E, Rebholz H. The Dopamine D5 receptor contributes to activation of cholinergic interneurons during L-DOPA induced dyskinesia. Sci Rep. 2020 02 13; 10(1):2542.
-
Krasnova IN, Betts ES, Dada A, Jefferson A, Ladenheim B, Becker KG, Cadet JL, Hohmann CF. Neonatal dopamine depletion induces changes in morphogenesis and gene expression in the developing cortex. Neurotox Res. 2007 Feb; 11(2):107-30.
-
Lee DC, Womble TA, Mason CW, Jackson IM, Lamango NS, Severs WB, Palm DE. 6-Hydroxydopamine induces cystatin C-mediated cysteine protease suppression and cathepsin D activation. Neurochem Int. 2007 Mar; 50(4):607-18.
-
Lee DC, Close FT, Goodman CB, Jackson IM, Wight-Mason C, Wells LM, Womble TA, Palm DE. Enhanced cystatin C and lysosomal protease expression following 6-hydroxydopamine exposure. Neurotoxicology. 2006 Mar; 27(2):260-76.
-
Chan CK, Burke SL, Zhu H, Piletz JE, Head GA. Imidazoline receptors associated with noradrenergic terminals in the rostral ventrolateral medulla mediate the hypotensive responses of moxonidine but not clonidine. Neuroscience. 2005; 132(4):991-1007.
-
Mazzio EA, Kolta MG, Reams RR, Soliman KF. Inhibitory effects of cigarette smoke on glial inducible nitric oxide synthase and lack of protective properties against oxidative neurotoxins in vitro. Neurotoxicology. 2005 Jan; 26(1):49-62.
-
Mazzio EA, Reams RR, Soliman KF. The role of oxidative stress, impaired glycolysis and mitochondrial respiratory redox failure in the cytotoxic effects of 6-hydroxydopamine in vitro. Brain Res. 2004 Apr 09; 1004(1-2):29-44.
-
Lamango NS, Charlton CG. Farnesyl-L-cysteine analogs block SAM-induced Parkinson's disease-like symptoms in rats. Pharmacol Biochem Behav. 2000 Aug; 66(4):841-9.
-
Head GA, Chan CK, Zhu H, Piletz JE. Dissociation of the effects of intramedullary monoamine neurotoxins on the hypotensive action of moxonidine and on immunodetected imidazoline and alpha 2-receptor proteins. Ann N Y Acad Sci. 1999 Jun 21; 881:300.
-
Johnson AE, Renner KJ, Allen D, Luine VN, Nock B, Feder HH. Noradrenergic regulation of alpha 1-receptors during the postnatal development of the guinea pig. Brain Res. 1987 Mar; 429(1):67-74.